Induction and function of CYR61 (CCNI) in prostatic stromal and epithelial cells: CYR61 is required for prostatic cell proliferation

Prostate

Volumn 61, Issue 4, 2004, Pages 305-317

  Sakamoto, Shinji ^a   Yokoyama, Masahiro ^a   Aoki, Michiko ^a   Suzuki, Kensuke ^a   Kakehi, Yoshiyuki ^b   Saito, Yutaka ^a  

^a JT Inc   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

BPH; CYR61; Enlargement; Proliferation; Suppressor

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BOVINE SERUM ALBUMIN; CYSTEINE RICH PROTEIN 61; GROWTH FACTOR; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL ADHESION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; CYR61 GENE; DISEASE COURSE; ENDOTHELIUM CELL; EPITHELIUM HYPERPLASIA; EXTRACELLULAR MATRIX; FIBROBLAST; GENE; GENE INDUCTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEIN FUNCTION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL;

CELL ADHESION; CELL LINE; CELL PROLIFERATION; EPITHELIAL CELLS; FETAL BLOOD; GENE EXPRESSION REGULATION; GROWTH SUBSTANCES; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; OLIGONUCLEOTIDES, ANTISENSE; PROSTATE; PROSTATIC HYPERPLASIA; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STROMAL CELLS;

EID: 9444232277     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20098     Document Type: Article

References (43)

1. Prostate enlargement: Benign prostatic hyperplasia by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health [Online]. Retrieved from http://kidney.niddk.nih.gov/kudiseases/pubs/ prostateenlargement/index.htm
2. Benign Prostatic Hyperplasia (BPH): Urology Channel [Online]. Retrieved from http://www.urologychannel.com/prostate/bph/index.shtml
3. Clifford GM, Farmer RD. Medical therapy for benign prostatic hyperplasia: A review of the literature. Eur Urol 2000;38:2-19.
4. Stoevelaar HJ, McDonnell J. Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations. Pharmacoeconomics 2001;19:131-153.
5. Benign Prostatic Hyperplasia Vol. 4 No. 2: St. James's Hospital [Online]. Retrieved from http://www.stjames.ie/ClinicalInformation/ NationalMedicinesInformationCentre/NMICBulletin/1998/ BenignProstaticHyperlasiaVol4No2/
6. Brigstock DR. The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr Rev 1999;20:189-206.
7. Perbal B. NOV (nephroblastoma overexpressed) and the CCN family of genes: Structural and functional issues. Mol Pathol 2001;54:57-79.
8. Kireeva ML, MO FE, Yang GP, Lau LF. Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion. Mol Cell Biol 1996;16:1326-1334.
9. Kolesnikova TV, Lau LF. Human CYR61-mediated enhancement of bFGF-induced DNA synthesis in human umbilical vein endothelial cells. Oncogene 1998;16:747-754.
10. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 1998;95:6355-6360.
11. 3 responsive immediate early gene in human fetal osteoblasts: Regulation by cytokines, growth factors, and serum. Endocrinology 1998;139: 1761-1770.
12. Tamura I, Rosenbloom J, Macarak E, Chaqour B. Regulation of Cyr61 gene expression by mechanical stretch through multiple signaling pathways. Am J Physiol Cell Physiol 2001;281:C1524-C1532.
13. Hilfiker A, Hilfiker-Kleiner D, Fuchs M, Kaminski K, Lichtenberg A, Rothkotter HJ, Schleifer B, Drexler H. Expression of CYR61, an angiogenic immediate early gene, in arteriosclerosis and its regulation by angiotensin II. Circulation 2002;106:254-260.
14. 2 as an adhesion receptor on peripheral blood monocytes for Cyr61 (CCN1) and connective tissue growth factor (CCN2): Immediate-early gene products expressed in atherosclerotic lesions. Blood 2002;99:4457-4465.
15. Wu KJ, Yee A, Zhu NL, Gordon EM, Hall FL. Characterization of differential gene expression in monkey arterial neointima following balloon catheter injury. Int J Mol Med 2000;6:433-440.
16. Pendurthi UR, Alien KE, Ezban M, Rao LV. Factor VIIa and thrombin induce the expression of Cyr61 and connective tissue growth factor, extracellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa x tissue factor-induced signal transduction. J Biol Chem 2000;275:14632-14641.
17. Xie D, Miller CW, O'Kelly J, Nakachi K, Sakashita A, Said JW, Gornbein J, Koeffler HP. Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem 2001;276:14187-14194.
18. Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 2001;61:8917-8923.
19. Sampath D, Winneker RC, Zhang Z. Cyr61, a member of the CCN family, is required for MCF-7 cell proliferation: regulation by 17β-estradiol and overexpression in human breast cancer. Endocrinology 2001;142:2540-2548.
20. Tsai MS, Hornby AE, Lakins J, Lupu R. Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res 2000;60:5603-5607.
21. Menendez JA, Mehmi I, Griggs DW, Lupu R. International Congress on Hormonal Steroids and Hormones and Cancer: The angiogenic factor CYR61 in breast cancer: Molecular pathology and therapeutic perspectives. Endocr Relat Cancer 2003;10:141-152.
22. Prakash K, Pirozzi G, Elashoff M, Munger W, Waga I, Dhir R, Kakehi Y, Getzenberg RH. Symptomatic and asymptomatic benign prostatic hyperplasia: Molecular differentiation by using microarrays. Proc Natl Acad Sci USA 2002;99:7598-7603.
23. Sakamoto S, Yokoyama M, Prakash K, Tsuruha J, Masamoto S, Getzenberg RH, Kakehi Y. Development of quantitative detection assays for CYR61 as a new marker for benign prostatic hyperplasia. J Biomol Screen 2003;8:701-711.
24. Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 2000;42:150-160.
25. Cabelin MA, Te AE, Kaplan SA. Benign prostatic hyperplasia: Challenges for the new millennium. Curr Opin Urol 2000;10:301-306.
26. Eaton CL. Aetiology and pathogenesis of benign prostatic hyperplasia. Curr Opin Urol 2003;13:7-10.
27. Renshaw MW, Ren XD, Schwartz MA. Growth factor activation of MAP kinase requires cell adhesion. EMBO J 1997;16:5592-5599.
28. Dedhar S. Cell-substrate interactions and signaling through ILK. Curr Opin Cell Biol 2000;12:250-256.
29. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999;285:1028-1032.
30. 3 integrin ligands to promote melanoma cell spreading and focal adhesion kinase phosphorylation. J Biol Chem 1999;274:22755-22762.
31. Park PW, Reizes O, Bernfield M. Cell surface heparan sulfate proteoglycans: Selective regulators of ligand-receptor encounters. J Biol Chem 2000;275:29923-29926.
32. Rogers C, Welt FG, Karnovsky MJ, Edelman ER. Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler Thromb Vase Biol 1996;16:1312-1318.
33. Bingley JA, Campbell JH, Hayward IP, Campbell GR. Inhibition of neointimal formation by natural heparan sulfate proteoglycans of the arterial wall. Ann NY Acad Sci 1997;811:238-244.
34. Grzeszkiewicz TM, Lindner V, Chen N, Lam SC, Lau LF. The angiogenic factor cysteine-rich 61 (CYR61, CCN1) supports vascular smooth muscle cell adhesion and stimulates chemotaxis through integrin 6P1 and cell surface heparan sulfate proteoglycans. Endocrinology 2002;143:1441-1450.
35. Latinkic BV, O'Brien TP, Lau LF. Promoter function and structure of the growth factor-inducible immediate early gene cyr61. Nucleic Acids Res 1991;19:3261-3267.
36. Story MT, Hopp KA, Molter M, Meier DA. Characteristics of FGF-receptors expressed by stromal and epithelial cells cultured from normal and hyperplastic prostates. Growth Factors 1994;10:269-280.
37. Ropiquet F, Giri D, Lamb DJ, Ittmann M. FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. J Urol 1999;162:595-599.
38. Kubota S, Hattori T, Shimo T, Nakanishi T, Takigawa M. Novel intracellular effects of human connective tissue growth factor expressed in Cos-7 cells. FEBS Lett 2000;474:58-62.
39. Yosimichi G, Kubota S, Hattori T, Nishida T, Nawachi K, Nakanishi T, Kamada M, Takano-Yamamoto T, Takigawa M. CTGF/Hcs24 interacts with the cytoskeletal protein actin in chondrocytes. Biochem Biophys Res Commun 2002;299:755-761.
40. Wahab NA, Brinkman H, Mason RM. Uptake and intracellular transport of the connective tissue growth factor: A potential mode of action. Biochem J 2001;359:89-97.
41. Chaqour B, Whitbeck C, Han JS, Macarak E, Horan P, Chichester P, Levin R. Cyr61 and CTGF are molecular markers of bladder wall remodeling after outlet obstruction. Am J Physiol Endocrinol Metab 2002;283:E765-E774.
42. Muramatsu Y, Tsujie M, Kohda Y, Pham B, Perantoni AO, Zhao H, Jo SK, Yuen PS, Craig L, Hu X, Star RA. Early detection of cysteine rich protein 61 (CYR61, CCN1) in urine following renal ischemic reperfusion injury. Kidney Int 2002;62:1601-1610.
43. Pilarsky CP, Schmidt U, Eissrich C, Stade J, Froschermaier SE, Haase M, Faller G, Kirchner TW, Wirth MP. Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer. Prostate 1998;36:85-91.